XNAS
PDEX
Market cap198mUSD
Oct 08, Last price
62.21USD
1D
-0.94%
1Q
-1.08%
Jan 2017
1,223.62%
Name
Pro-Dex Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Pro-Dex, Inc. focuses on the development and manufacturing of advanced motorized surgical instruments. These sophisticated tools are supplied globally to original equipment manufacturers (OEMs) in the medical device sector. Their product portfolio features versatile, autoclavable (sterilization-friendly) surgical drivers and shavers, available in both battery-powered and electric models, often equipped with multi-functional capabilities. These instruments are primarily employed in orthopedic, thoracic, and craniomaxillofacial surgical procedures. Beyond its core manufacturing, Pro-Dex also offers expert consulting services, covering engineering, quality assurance, and regulatory compliance. Furthermore, the company manufactures and distributes rotary air motors to various industrial clients. Founded in 1978, Pro-Dex, Inc. maintains its corporate headquarters in Irvine, California.
Key people
Non-Executive Independent Chairman of the Board · since 2013
Richard Van Kirk
President, Chief Executive Officer, Chief Operating Officer, Director · since 2015
Alisha Charlton
Chief Financial Officer, Corporate Secretary · since 2021
Angelita Domingo
Director · since 2021
Independent Director · since 2013
William Farrell
Independent Director · since 2013
David Hovda
Independent Director · since 2013
Katrina Philp
Independent Director · since 2019
Legal address
c/o The Corporation Company, 7700 E Arapahoe Rd Ste 220
Centennial, CO 80112
US
Centennial, CO 80112
US
Headquarters
2361 McGaw Ave
Irvine, CA 92614
US
Irvine, CA 92614
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||